Abstract
Objective:
The fetus is exposed to magnesium administered to the pregnant mother. However, there is controversy regarding magnesium-related neonatal adverse outcomes, largely driven by a limited understanding of the factors that influence neonatal serum magnesium concentrations and associated outcomes. The objective of this study was to examine the relationship between antenatal maternal magnesium dose and serum concentrations, neonatal serum magnesium concentration and immediate neonatal outcomes.
Study Design:
A retrospective study was conducted at a community-based teaching hospital. Neonatal serum magnesium concentrations within 48 h of birth were used to stratify magnesium-exposed neonates into three groups: group 1: <2.5 mg dl−1, group 2: ⩾2.5 to <4.5 mg dl−1, and group 3:⩾4.5 mg dl−1. Immediate neonatal outcomes were compared between the three groups. Total maternal magnesium dose and serum magnesium concentrations before the delivery were correlated with neonatal serum magnesium concentrations and outcomes.
Results:
Of the 304 mother–baby dyads between 24 and 34 weeks gestation, 237 received antenatal magnesium. Neonatal serum magnesium concentration was 3.14±0.83 mg dl−1 in exposed and 1.96±0.42 mg dl−1 in unexposed neonates (P<0.001). Compared with group 2, neonates had higher odds of grade 3 or 4 intraventricular hemorrhage in group 1 (adjusted odds ratio (AOR) 5.95 (95% confidence interval (CI) 1.05 to 33.66)) and group 3 (AOR 8.42 (95% CI 1.35 to 52.54)). Group 3 neonates also had increased odds of periventricular leukomalacia (AOR: 5.37 (95% CI 1.02 to 28.28) compared with group 2 neonates. Predictors of neonatal serum magnesium concentrations included maternal magnesium dose (r=0.66, P<0.0001), duration of therapy (r=0.70, P<0.0001) and serum concentration (r=0.72, P<0.001).
Conclusion:
The between-group differences highlight that there is a therapeutic range of neonatal serum magnesium concentrations for neuroprotective effects of antenatal magnesium sulfate, while concentrations outside of this range may be associated with adverse neonatal outcomes. Further studies are needed to determine the optimal dose and duration of maternal magnesium to minimize adverse neonatal outcomes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D . Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; 21 (1): CD004661.
Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M . Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet 1997; 350 (9090): 1517–1518.
Crowther CA, Hiller JE, Doyle LW, Haslam RR, Australian Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. J Am Med Assoc 2003; 290: 2669–2676.
Marret S, Marpeau L, Follet-Bouhamed C, Cambonie G, Astruc D, Delaporte B et al. Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective PREMAG trial. Gynecol Obstet Fertil 2008; 36 (3): 278–288.
Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM et al. A randomized controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008; 359: 895–905.
Basu SK, Chickajajur V, Lopez V, Bhutada A, Pagala M, Rastogi S . Immediate clinical outcomes in preterm neonates receiving antenatal magnesium for neuroprotection. J Perinat Med 2011; 40 (2): 185–189.
Borja-Del-Rosario P, Basu SK, Haberman S, Bhutada A, Rastogi S . Neonatal serum magnesium concentrations are determined by total maternal dose of magnesium sulfate administered for neuroprotection. J Perinat Med 2014; 42 (2): 207–211.
Stigson L, Kjellmer I . Serum concentrations of magnesium at birth related to complications of immaturity. Acta Paediatr 1997; 86 (9): 991–994.
Mittendorf R, Dambrosia J, Dammann O, Pyrde PG, Lee KS, Ben-Ami TE et al. Association between maternal serum ionized magnesium concentrations at delivery and neonatal intraventricular hemorrhage. J Pediatr 2002; 140 (5): 540–546.
Murata T, Dietrich HH, Horiuchi T, Hongo K, Dacey RG Jr. . Mechanisms of magnesium-induced vasodilation in cerebral penetrating arterioles. Neurosci Res 2016; 107: 57–62.
Gawaz M, Ott I, Reininger AJ, Neumann FJ . Effects of magnesium on platelet aggregation and adhesion. Magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. Thromb Haemost 1994; 72 (6): 912–918.
Guzin K, Goynumer G, Gokdagli F, Turkgeldi E, Gunduz G, Kayabasoglu F . The effect of magnesium sulfate treatment on blood biochemistry and bleeding time in patients with severe preeclampsia. J Matern Fetal Neonatal Med 2010; 23 (5): 399–402.
Dickens BF, Weglicki WB, Li YS, Mak IT . Magnesium deficiency in vitro enhances free radical-induced intracellular oxidation and cytotoxicity in endothelial cells. FEBS Lett 1992; 311 (3): 187–191.
Wiles ME, Wagner TL, Weglicki WB . Effect of acute magnesium deficiency (MgD) on aortic endothelial cell (EC) oxidant production. Life Sci 1997; 60 (3): 221–236.
Maier JA . Endothelial cells and magnesium: implications in atherosclerosis. Clin Sci (Lond) 2012; 122 (9): 397–407.
Chardain A, Mesnage V, Alamowitch S, Bourdain F, Crozier S, Lenglet T et al. Posterior reversible encephalopathy syndrome (PRES) and hypomagnesemia: a frequent association? Rev Neurol (Paris) 2016; 172 (6-7): 384–388.
Te Riele MG, Verrips A . Severe hypomagnesaemia causing reversible cerebellopathy. Cerebellum 2014; 13 (5): 659–662.
American College of Obstetricians and Gynecologists Committee on Obstetric Practice; Society for Maternal-Fetal Medicine. Committee Opinion No. 455: magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol 2010; 115 (3): 669–671.
American College of Obstetricians and Gynecologists Committee on Obstetric Practice Society for Maternal-Fetal Medicine. Committee Opinion No. 573: magnesium sulfate use in obstetrics. Obstet Gynecol 2013; 122 (3): 727–728.
McPherson JA, Rouse DJ, Grobman WA, Palatnik A, Stamilio DM . Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstet Gynecol 2014; 124 (4): 749–755.
Redman C, Jacobson SL, Russel R de Swiet’s medical disorders in obstetric practice 5th edn.Chapter 6 Hypertension in Pregnancy. Wiley-Blackwell: West Sussex, UK, 2010, p 169.
Mittendorf R, Stratford R, Khoshnood B, Lee KS, Pryde PG . Persistence of elevated serum magnesium concentrations in the neonate. Am J Obstet Gynecol 2001; 184: S50.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Narasimhulu, D., Brown, A., Egbert, N. et al. Maternal magnesium therapy, neonatal serum magnesium concentration and immediate neonatal outcomes. J Perinatol 37, 1297–1303 (2017). https://doi.org/10.1038/jp.2017.132
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2017.132
This article is cited by
-
Antenatal Magnesium Sulfate and adverse gastrointestinal outcomes in Preterm infants—a systematic review and meta-analysis
Journal of Perinatology (2023)
-
Impact of quality improvement outreach education on the incidence of acute brain injury in transported neonates born premature
Journal of Perinatology (2022)
-
Neonatal magnesium levels are safe after maternal MgSO4 administration: a comparison between unexposed preterm neonates and neonates exposed for fetal neuroprotection or maternal eclampsia prevention—a cohort study
European Journal of Pediatrics (2022)